Nurix Therapeutics
1700 Owens Street
Suite 205
San Francisco
California
94158
United States
Tel: 415-660-5320
Website: https://www.nurixtx.com/
Email: Info@nurix-inc.com
About Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.
Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.
120 articles about Nurix Therapeutics
-
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
3/25/2024
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that it is part of a diverse research team of international experts selected as awardees in this year’s Cancer Grand Challenges competition.
-
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
3/20/2024
Nurix Therapeutics, Inc. (Nasdaq: NRIX) today disclosed the discovery and structure of NX-1607 in the First Time Disclosures session at the American Chemical Society Spring 2024 meeting in New Orleans, LA.
-
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 TrialNurix cleared to introduce new chirally controlled NX-2127 drug product and resume enrollment of new patients into the study
3/11/2024
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that the U.S. Food and Drug Administration has lifted the partial clinical hold on the U.S. Phase 1a/1b study evaluating NX-2127 in adults with relapsed/refractory B-cell malignancies.
-
Nurix Therapeutics to Participate in Upcoming March 2024 Investor Conferences
3/6/2024
Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that Hans van Houte, Nurix’s chief financial officer, and Jason Kantor, Ph.D., Nurix’s chief business officer will participate in the following conferences in March.
-
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
3/5/2024
Nurix Therapeutics, Inc. announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, is invited as a featured speaker in two sessions at the American Association for Cancer Research 2024 Annual Meeting, which will be held from April 5-10, 2024, in San Diego, CA.
-
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
2/15/2024
Nurix Therapeutics, Inc. reported financial results for the fiscal quarter and fiscal year ended November 30, 2023, and provided a corporate update.
-
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
2/1/2024
Nurix Therapeutics, Inc. announced the publication of a manuscript in the journal Science titled: “Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127”.
-
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
1/16/2024
Nurix Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK), for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia.
-
Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases
1/8/2024
Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, outlined key objectives and anticipated milestones for 2024 and provided an overview of recent progress in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference.
-
Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix’s achievements in 2023 and major goals for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 p.m. PT.
-
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting
12/11/2023
Nurix Therapeutics, Inc. today presented positive clinical data from its orally available degraders of BTK, NX-5948 and NX-2127, which are being evaluated in separate Phase 1a/1b clinical trials in patients with relapsed or refractory (r/r) B-cell malignancies, including CLL, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), primary CNS lymphoma (PCNS), and Waldenström’s macroglobulinemia (WM).
-
Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting
12/4/2023
Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that it will host a live webcast to review clinical data from the Phase 1 clinical trials of its Bruton’s tyrosine kinase (BTK) degrader programs, NX-5945 and NX-2127, which are being evaluated in patients with relapsed or refractory B cell malignancies, at 8:30 p.m. PST (11:30 p.m. EST) on Monday, December 11, 2023.
-
Nurix Therapeutics to Participate in Upcoming November 2023 Investor Conferences
11/7/2023
Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in November.
-
Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting
11/2/2023
Nurix Therapeutics, Inc. announced that clinical data will be presented for its two BTK degrader programs, NX-5948 and NX-2127, in two posters at the 65th American Society of Hematology Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA.
-
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 TrialCurrently enrolled patients may continue receiving NX-2127
11/1/2023
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on U.S. Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies.
-
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
10/12/2023
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended August 31, 2023, and provided a corporate update.
-
After its prostate cancer therapy was not included in Medicare’s initial drug price negotiation list, Astellas dismissed its Inflation Reduction Act lawsuit this week, while Illumina got new leadership.
-
The companies have started a collaboration worth up to $3.4 billion to develop a portfolio of degrader-antibody conjugates, a potentially new class of antibodies that selectively kill cancer cells.
-
Nurix Therapeutics to Participate in Upcoming September 2023 Investor Conferences
8/31/2023
Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer will participate in the following conferences in September.
-
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
7/13/2023
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended May 31, 2023, and provided a corporate update.